GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

FSBW · Dec 31, 2024

FS Bancorp, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-25-008049Bank
Sequential deposit growth0thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.deposits

-3.62% · CORE · VALID

Net-income growth35thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

-2.85% · CORE · VALID

Interest-income growth45thOwn-history percentile · N=20
Evidence method

Yoy · gp.financial.interest_income

10.55% · CORE · VALID

Cash and equivalents20thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$31.6M · CORE · VALID

Sequential loan growth25thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.loans

1.55% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History57 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Decreased
Previous
1.87%
Current
-3.62%
Delta
-5.49%
Earnings Growth Decreased
Previous
14.89%
Current
-2.85%
Delta
-17.74%
Interest Income Growth Increased
Previous
8.72%
Current
10.55%
Delta
1.83%
Liquidity Decreased
Previous
$40.3M
Current
$31.6M
Delta
-$8.7M
Loan Growth Decreased
Previous
3.71%
Current
1.55%
Delta
-2.16%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.